VPD-737
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa
Conditions
Epidermolysis Bullosa, Pruritus
Trial Timeline
Aug 31, 2016 → Jul 27, 2018
NCT ID
NCT02654483About VPD-737
VPD-737 is a phase 2 stage product being developed by Vyne Therapeutics for Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT02654483. Target conditions include Epidermolysis Bullosa, Pruritus.
What happened to similar drugs?
0 of 7 similar drugs in Epidermolysis Bullosa were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02654483 | Phase 2 | Completed |
Competing Products
13 competing products in Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 36 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 44 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 29 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 37 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 37 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 32 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 37 |
| SD-101-6.0 cream | Amicus Therapeutics | Phase 3 | 29 |
| SD-101 dermal cream (6%) | Amicus Therapeutics | Phase 2 | 24 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 22 |
| EB-101 | Abeona Therapeutics | Phase 3 | 30 |
| EB-101 Surgical application of RDEB wounds | Abeona Therapeutics | Phase 3 | 34 |
| Serlopitant Tablet + Placebo Oral Tablet | Vyne Therapeutics | Phase 2 | 25 |